Get pre-screened

Remember what's important.

Get evaluated for a clinical trial

Get Evaluated for a Memory Trial

"*" indicates required fields

Phone

This field is for validation purposes and should be left unchanged.

This field is hidden when viewing the form

Untitled

Name*

First Last

Phone*

Email

Message

Simple Steps to Get Started

1. Get Pre-Screened

Start by signing up to be pre-screened for eligibility in the clinical trial.

2. Visit Our Office

Come for an in-office assessment of your health, and meet the care team.

3. Enroll in a Clinical Trial

If your results show you meet the trial criteria, you may be able to participate in a clinical trial.

Ready to Take the First Step?

Sign up today and take your first quick step toward better health. It’s easy and completely free!

Start your journey

Medical physician talking to his patient. African american patient in a checkup with his doctor. Confident healthcare specialist talking to a patient in an exam. Medical professional in a clinic

2-06-17-25OfficeHeadshots-332-scaled-e1750903184392

About The Principal Investigator

DR. MARK RAPP, MD

Principal Investigator, CNS Division Chief

Dr. Mark Rapp is a board-certified neurologist and Principal Investigator at Basil Clinical, where he leads the CNS division. He specializes in clinical trials targeting neuropsychiatric and neurologic disorders, with a focus on Alzheimer’s disease, Major Depressive Disorder, and related conditions.

Dr. Rapp completed his residency at the Harvard Medical School Neurology Residency Program at Beth Israel Deaconess Medical Center and Boston Children’s Hospital. During his training, he witnessed firsthand the limitations patients face in accessing effective treatments. This experience sparked a deep commitment to advancing care through research, ultimately leading him to pursue a full-time career in clinical trials.

He brings a rigorous, patient-centered approach to brain health research, emphasizing both scientific integrity and compassionate care. Dr. Rapp is particularly focused on expanding equitable access to clinical trials for underrepresented populations and addressing the psychosocial barriers that often complicate care in neuropsychiatric disorders.